Atb Cap Markets Decreases Earnings Estimates for Tilray

Tilray Inc (NASDAQ:TLRY) – Equities research analysts at Atb Cap Markets dropped their FY2028 earnings per share estimates for shares of Tilray in a research note issued on Monday, December 16th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of $0.01 per share for the year, down from their prior forecast of $0.06. The consensus estimate for Tilray’s current full-year earnings is ($0.14) per share.

Tilray (NASDAQ:TLRY) last released its quarterly earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The company had revenue of $200.00 million for the quarter, compared to analysts’ expectations of $218.70 million. During the same period in the previous year, the business posted ($0.10) earnings per share. The business’s quarterly revenue was up 13.0% compared to the same quarter last year.

Separately, Roth Mkm decreased their target price on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research report on Friday, October 11th.

Tilray Stock Performance

NASDAQ TLRY opened at $1.16 on Wednesday. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -4.30 and a beta of 2.08. Tilray has a twelve month low of $1.15 and a twelve month high of $2.97. The stock has a fifty day simple moving average of $1.46 and a 200 day simple moving average of $1.66. The company has a quick ratio of 1.57, a current ratio of 2.47 and a debt-to-equity ratio of 0.08.

Insider Activity

In related news, CFO Carl A. Merton bought 26,000 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were bought at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the transaction, the chief financial officer now directly owns 26,000 shares of the company’s stock, valued at approximately $35,360. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.87% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tilray

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Synovus Financial Corp boosted its holdings in Tilray by 176.7% in the third quarter. Synovus Financial Corp now owns 36,092 shares of the company’s stock worth $64,000 after acquiring an additional 23,046 shares in the last quarter. Barclays PLC raised its position in shares of Tilray by 600.4% during the third quarter. Barclays PLC now owns 204,144 shares of the company’s stock worth $359,000 after purchasing an additional 174,997 shares during the period. Toronto Dominion Bank lifted its holdings in shares of Tilray by 454.5% in the 3rd quarter. Toronto Dominion Bank now owns 128,923 shares of the company’s stock worth $227,000 after purchasing an additional 105,671 shares in the last quarter. XTX Topco Ltd grew its position in Tilray by 1,079.7% in the 3rd quarter. XTX Topco Ltd now owns 281,504 shares of the company’s stock valued at $495,000 after purchasing an additional 257,641 shares during the period. Finally, State Street Corp raised its holdings in Tilray by 4.7% during the third quarter. State Street Corp now owns 1,961,338 shares of the company’s stock worth $3,452,000 after buying an additional 88,079 shares during the last quarter. 9.35% of the stock is owned by institutional investors.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.